Daniel C. Adelman
2019 - Aimmune Therapeutics
In 2019, Daniel C. Adelman earned a total compensation of $1.9M as Chief Medical Officer at Aimmune Therapeutics, a 10% decrease compared to previous year.
Compensation breakdown
| Bonus | $4,279 |
|---|---|
| Non-Equity Incentive Plan | $179,706 |
| Option Awards | $1,007,504 |
| Salary | $445,700 |
| Stock Awards | $281,675 |
| Other | $2,000 |
| Total | $1,920,864 |
Adelman received $1M in option awards, accounting for 52% of the total pay in 2019.
Adelman also received $4.3K in bonus, $179.7K in non-equity incentive plan, $445.7K in salary, $281.7K in stock awards and $2K in other compensation.
Rankings
In 2019, Daniel C. Adelman's compensation ranked 6,152nd out of 13,971 executives tracked by ExecPay. In other words, Adelman earned more than 56.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,152 out of 13,971 | 56th |
Division Manufacturing | 2,309 out of 5,695 | 60th |
Major group Chemicals And Allied Products | 839 out of 2,194 | 62nd |
Industry group Drugs | 707 out of 1,880 | 62nd |
Industry Pharmaceutical Preparations | 522 out of 1,392 | 63rd |
Source: SEC filing on April 9, 2020.
Adelman's colleagues
We found four more compensation records of executives who worked with Daniel C. Adelman at Aimmune Therapeutics in 2019.